Loading stock data…
AGEN
$3.84-0.07 (-1.79%)
Market ClosedLast close May 1
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agenus Inc. in the Healthcare sector is trading at $3.84. The stock is currently 48% below its 52-week high of $7.34, remaining 4.5% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why AGEN maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.84
Potential Downside
100%
Whystock Fair Value$0.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identificati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$151.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
82.71%
Volume
Today's trading volume
513,907
Recent News
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?
CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.